A patient undergoes treatment - immunotherapy, integrative immune therapies, dendritic cell therapy, or a combination of these - and the initial response is encouraging. Labs shift. The immune system learns and engages. Symptoms and scans may improve. There is a sense of a ‘turning point’.
And, then, gradually the response plateaus or stabilizes. Sometimes it reverses. This is frequently determined as ‘treatment failure.’
There’s a perception that the immunotherapy is an isolated event - once administered, it’s complete. The immune system doesn’t function is isolation. Immunotherapy is designed to initiate a process. This process will include: immune activation, antigen recognition, cytotoxic engagement and, hopefully, immune memory.
These steps are the starting line.
After this part, the race really begins. The goal is not activation, the goal is sustained recognition. For that to occur, T-cells must function well, antigen presentation must continue and the microenvironment must remain permissive to this process.
It’s rarely a clear cause-and-effect situation, but there are some indications we can take note of...
The Terrain Drift
Rising inflammatory burden, indications of hepatic stress, a movement toward metabolic dysfunction and worsening immune response are all signs that the microenvironment is no longer allowing an optimal, appropriate response to take place. Most of the time, imaging follows labs.
Conventionally, assessment is centered on imaging, and at times, tumor markers. While these have value, they do not fully capture what is happening within the immune system or the terrain. Just as meaningful, are trends in lymphocyte counts, neutrophil-to-lymphocyte ratio, LDH, CRP and ESR patterns, along with the evolution of patient symptoms. These markers provide insight into whether the system is engaging, stabilizing, or beginning to drift, often before changes are visible on imaging.
A Sustained Response
Post-therapy management is not about intensifying treatment. It’s not about adding more therapies or pushing the system harder.
It’s about maintaining the conditions that allowed the response to occur in the first place.
Immune competence has to be preserved—T-cells must remain viable, responsive, and capable of continued engagement. Metabolic stability becomes critical, as shifts in glucose regulation, mitochondrial function, and energy availability directly impact immune performance. Inflammatory signaling must remain controlled—not suppressed, but regulated—so that the system can respond without drifting back into chronic dysfunction. And underlying all of this is hepatic processing capacity, which determines how effectively the body can manage inflammatory load, toxins, and immune byproducts.
This requires ongoing intervention—but not escalation. It requires precision, consistency, and an understanding that the system needs to be supported, not overwhelmed.
Clinical Reality
Stability is not passive.
The absence of progression does not mean the system is stable—it means the system is holding under current conditions.
That distinction matters.
What appears stable on imaging may still reflect a system under strain. Lab trends often begin to shift before scans do. Subtle changes in inflammatory markers, immune cell counts, or patient-reported symptoms can indicate that the terrain is beginning to drift.
If those underlying conditions deteriorate, even slightly, the response follows. Not abruptly, but gradually. What was once controlled becomes less coordinated, less effective, and eventually insufficient.
This is where most responses are lost—not at the time of treatment, but in the period that follows.
My Closing Position
Immunotherapy is not the endpoint.
It is the inflection point.
It initiates a process—but it does not sustain it.
What follows determines whether the response becomes durable—or transient. Whether immune recognition is maintained—or fades. Whether the terrain continues to support the response—or begins to work against it.
The treatment creates the opportunity.
The system determines whether it lasts.
References
Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39(1):1–10.
Topalian SL, Drake CG, Pardoll DM. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015;27(4):450–461.
Leone RD, Powell JD. Metabolism of immune cells in cancer. Nature Reviews Cancer. 2020;20:516–531.
Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic Instruction of Immunity. Cell. 2017;169(4):570–586.
Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine. 2018;24:541–550.